Adaptive Biotechnologies Corporation
ADPT
$9.29
-$0.22-2.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.44M | 47.46M | 46.44M | 43.19M | 41.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.44M | 47.46M | 46.44M | 43.19M | 41.87M |
| Cost of Revenue | 16.98M | -44.64M | 40.83M | 23.49M | 18.05M |
| Gross Profit | 35.46M | 92.09M | 5.61M | 19.70M | 23.82M |
| SG&A Expenses | 40.45M | 39.63M | 37.81M | 38.21M | 41.92M |
| Depreciation & Amortization | 419.00K | 428.00K | 428.00K | 424.00K | 423.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.05M | 81.30M | 79.07M | 83.30M | 90.64M |
| Operating Income | -29.60M | -33.84M | -32.63M | -40.11M | -48.76M |
| Income Before Tax | -29.83M | -33.72M | -32.10M | -46.25M | -47.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.83M | -33.72M | -32.10M | -46.25M | -47.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -22.00K | 25.00K | 26.00K | 26.00K | 26.00K |
| Net Income | -29.85M | -33.69M | -32.07M | -46.22M | -47.51M |
| EBIT | -29.60M | -33.84M | -32.63M | -40.11M | -48.76M |
| EBITDA | -24.87M | -29.39M | -28.04M | -35.11M | -43.55M |
| EPS Basic | -0.20 | -0.23 | -0.22 | -0.31 | -0.33 |
| Normalized Basic EPS | -0.13 | -0.15 | -0.14 | -0.17 | -0.21 |
| EPS Diluted | -0.20 | -0.23 | -0.22 | -0.31 | -0.33 |
| Normalized Diluted EPS | -0.13 | -0.15 | -0.14 | -0.17 | -0.21 |
| Average Basic Shares Outstanding | 149.20M | 147.68M | 147.52M | 147.41M | 145.79M |
| Average Diluted Shares Outstanding | 149.20M | 147.68M | 147.52M | 147.41M | 145.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |